|
|
|
Volumn 13, Issue 14, 2002, Pages
|
|
Tamoxifen and raloxifene may benefit women at high risk for breast cancer.
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTINEOPLASTIC AGENT;
RALOXIFENE;
SELECTIVE ESTROGEN RECEPTOR MODULATOR;
TAMOXIFEN;
ARTICLE;
BREAST TUMOR;
CHEMOPROPHYLAXIS;
CLINICAL TRIAL;
FEMALE;
HUMAN;
PRACTICE GUIDELINE;
RISK ASSESSMENT;
RISK FACTOR;
TREATMENT OUTCOME;
UNITED STATES;
ANTICARCINOGENIC AGENTS;
BREAST NEOPLASMS;
CHEMOPREVENTION;
CLINICAL TRIALS;
FEMALE;
HUMANS;
PRACTICE GUIDELINES;
RALOXIFENE;
RISK ASSESSMENT;
RISK FACTORS;
SELECTIVE ESTROGEN RECEPTOR MODULATORS;
TAMOXIFEN;
TREATMENT OUTCOME;
UNITED STATES;
|
|
EID: 0037178933
PISSN: 10505636
EISSN: None
Source Type: Journal
DOI: None Document Type: Article |
|
Times cited : (4)
|
|
References (0)
|
